| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 34.77 | -63 |
| Intrinsic value (DCF) | 2.94 | -97 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
ABIVAX SA (ABVX.PA) is a clinical-stage biotechnology company headquartered in Paris, France, focused on discovering and optimizing novel therapeutics for inflammatory diseases, infectious diseases, and cancer. The company's lead candidate, ABX464, is in Phase IIb clinical trials for ulcerative colitis and Crohn's disease, with additional trials for rheumatoid arthritis and COVID-19. ABIVAX is also developing ABX196, an immune enhancer in Phase 1/2 trials for hepatocellular carcinoma, and has research programs targeting Dengue fever, influenza, and respiratory syncytial virus. With strategic collaborations with leading French research institutions like CNRS, the University of Montpellier, and Institut Curie, ABIVAX leverages cutting-edge science to address unmet medical needs. The company operates in the high-growth biotechnology sector, where innovation in immunology and oncology presents significant commercial opportunities. Despite being pre-revenue, ABIVAX's diversified pipeline positions it as a promising player in next-generation therapies for chronic and infectious diseases.
ABIVAX presents a high-risk, high-reward investment opportunity due to its clinical-stage pipeline targeting large markets like inflammatory bowel disease (IBD) and oncology. The company's lead candidate, ABX464, has shown potential in Phase II trials for ulcerative colitis and Crohn's disease, with possible applications in HIV and COVID-19. However, as a pre-revenue biotech, ABIVAX carries substantial financial risk, evidenced by a net loss of €176.2M in the latest period and negative operating cash flow. The stock's high beta (1.58) reflects volatility typical of developmental biotechs. Investors should monitor clinical trial progress, particularly ABX464's Phase IIb data, and the company's ability to secure additional funding given its €144.2M cash position against a €97.4M debt load. Success in pivotal trials could make ABIVAX an attractive acquisition target for larger pharma firms seeking immunology assets.
ABIVAX competes in the crowded immunology and oncology biotech space, differentiating itself through ABX464's novel mechanism targeting RNA splicing to modulate inflammation. In IBD (ulcerative colitis/Crohn's), ABIVAX faces entrenched competitors like AbbVie's Humira and Johnson & Johnson's Stelara, but ABX464's oral administration and potential disease-modifying effects could offer advantages over injectable biologics if proven effective. The oncology pipeline (ABX196) enters a highly competitive hepatocellular carcinoma market dominated by Roche's Tecentriq/Bevacizumab combo. ABIVAX's academic collaborations provide research credibility but lack the commercialization infrastructure of larger peers. Financially, the company's €320M market cap is modest compared to clinical-stage immunology peers, reflecting higher risk from its unproven platform. Pipeline breadth across inflammation, virology, and oncology provides diversification but risks resource dilution. ABIVAX's French base offers cost advantages versus US biotechs but may limit investor visibility. Near-term competitiveness hinges on ABX464's Phase IIb data quality and partnership potential to offset its limited commercial capabilities.